Skip to main content
UniHealth

Doctor search

John W Day, MD

Neurology · Stanford

NPI 1447291992

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Day’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G52734 · Current

Licensed to practise in California · since 2011 · expires 2027-04-30 · University of Minnesota Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$5,630

Medicare paid this office $5,630 for 37 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)17$1,952$108

Who their Medicare patients are

37 Original Medicare patients in 2024. Average age 63 · Under 65 41% · Women 49% · Health risk score 1.50. At or below the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 57% · Diabetes 32%.

The office billed $24,443, Medicare allowed $8,007 and paid $5,630; for 53 services of 9 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243753631.50$24,443$5,630
20233458661.32$27,762$4,953
20225399611.17$39,116$7,981
202174189611.53$88,860$15,426
202068105631.59$44,551$9,871
201977124631.63$22,834$12,085
201883114641.54$18,442$10,735
201789146611.72$42,219$12,933
201677122631.52$44,057$12,427
201583135641.59$40,067$13,322
2014116226661.40$84,412$22,427
2013107163671.55$59,209$18,382

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Long return visit (40+ min)26$3,234$115
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or16$466$23

2022: 2 services

Original Medicare services billed in 2022
Long return visit (40+ min)41$5,803$109
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or23$737$24

2021: 2 services

Original Medicare services billed in 2021
Long return visit (40+ min)62$10,707$127
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or43$2,157$28

2020: 1 service

Original Medicare services billed in 2020
Long return visit (40+ min)56$7,313$96

2019: 2 services

Original Medicare services billed in 2019
Long return visit (40+ min)63$8,505$95
New patient visit (60+ min)16$2,437$152

2018: 3 services

Original Medicare services billed in 2018
Long return visit (40+ min)65$6,744$86
New patient visit (60+ min)17$2,272$134
Long return visit (40+ min)11$1,097$100

2017: 2 services

Original Medicare services billed in 2017
Long return visit (40+ min)75$9,917$89
New patient visit (60+ min)16$2,042$128

2016: 2 services

Original Medicare services billed in 2016
Long return visit (40+ min)63$9,314$95
New patient visit (60+ min)22$2,989$136

2015: 2 services

Original Medicare services billed in 2015
Long return visit (40+ min)65$9,807$91
New patient visit (60+ min)22$3,266$148

2014: 2 services

Original Medicare services billed in 2014
Long return visit (40+ min)68$9,309$93
New patient visit (60+ min)49$6,961$142

2013: 3 services

Original Medicare services billed in 2013
New patient visit (60+ min)52$7,509$144
Long return visit (40+ min)47$6,807$95
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,442$174

Medicaid work

$1,577 in 2018

Medicaid paid $1,577 for 27 billed services this clinician did in 2018, up to 14 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2018
Long return visit (40+ min)13$1,117
Service14$460
Medicaid work by year
201827214$1,577

Drugs they prescribed that Part D paid

$588,351

Pharmacies billed $588,351 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 39) in 2024. Too few prescriptions to compare fairly with other clinicians.

16 generic and 23 brand-name prescriptions · $588,351 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Skyclarys13$406,626$31,279

Year by year

Part D prescribing by year
202439None0% (0)59%$588,351
202377150% (0)44%$717,243
2022131210% (0)35%$883,932
202110723None27%$439,747
202092190% (0)16%$41,913
201913927None27%$229,518
201812032None19%$89,194
2017129230% (0)19%$48,696
2016134260% (0)27%$27,096
2015122210% (0)16%$18,468
20143921NoneNone$2,066
20136918None35%$27,634

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Part D drugs prescribed in 2023
Evrysdi24$608,678$25,362
Tizanidine12$359$30

2022: 4 drugs

Part D drugs prescribed in 2022
Evrysdi34$860,533$25,310
Nuedexta12$18,275$1,523
Mycophenolate Mofetil11$845$77
Tizanidine15$234$16

2021: 4 drugs

Part D drugs prescribed in 2021
Evrysdi16$418,247$26,140
Nuedexta12$17,121$1,427
Tizanidine12$180$15
Fluoxetine11$48$4

2020: 2 drugs

Part D drugs prescribed in 2020
Nuedexta12$16,082$1,340
Riluzole17$5,475$322

2019: 3 drugs

Part D drugs prescribed in 2019
Radicava16$190,052$11,878
Nuedexta15$20,736$1,382
Riluzole44$8,120$185

2018: 3 drugs

Part D drugs prescribed in 2018
Nuedexta18$27,433$1,524
Riluzole39$8,677$222
Baclofen17$341$20

2017: 3 drugs

Part D drugs prescribed in 2017
Riluzole25$22,843$914
Nuedexta24$20,013$834
Gabapentin17$2,143$126

2016: 3 drugs

Part D drugs prescribed in 2016
Nuedexta21$15,063$717
Riluzole35$7,607$217
Gabapentin20$1,295$65

2015: 2 drugs

Part D drugs prescribed in 2015
Nuedexta12$7,983$665
Riluzole47$7,112$151

Money from drug and device companies

$21,660 in 2025

Industry payments by year
2025711$21,559$21,660
202466$13,920$14,012
2023854$42,673$62,785
2022943$50,293$58,328
2021321$12,840$20,907
2020463$19,925$42,941
20197140$28,245$73,609

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
F. Hoffmann-La Roche AGNone$5,848
3 payments
  • Consulting · 2025-11-19 · $2,800
  • Consulting · 2025-06-27 · $1,960
  • Consulting · 2025-04-01 · $1,088
GenzymeNexviazyme$3,975
2 payments
  • Paid to speak or teach for Nexviazyme · 2025-08-16 · $1,250
  • Consulting · 2025-01-27 · $2,725
Sarepta TherapeuticsElevidys$3,475
2 payments
  • Meals · 2025-07-28 · $100
  • Consulting for Elevidys · 2025-04-24 · $3,375
Novartis Pharma AGZolgensma$3,362
1 payment
  • Consulting for Zolgensma · 2025-07-25 · $3,362
Sanofi US ServicesNone$2,725
1 payment
  • Consulting · 2025-01-27 · $2,725
Novartis PharmaceuticalsZolgensma$1,650
1 payment
  • Consulting for Zolgensma · 2025-04-24 · $1,650
See all 11 published payments
Every published payment
F. Hoffmann-La Roche AGConsulting · 2025-11-19None$2,800
GenzymePaid to speak or teach · 2025-08-16Nexviazyme$1,250
Sarepta TherapeuticsMeals · 2025-07-28None$100
Novartis Pharma AGConsulting · 2025-07-25Zolgensma$3,362
Argenx USConsulting · 2025-07-23None$625
F. Hoffmann-La Roche AGConsulting · 2025-06-27None$1,960
Novartis PharmaceuticalsConsulting · 2025-04-24Zolgensma$1,650
Sarepta TherapeuticsConsulting · 2025-04-24Elevidys$3,375
F. Hoffmann-La Roche AGConsulting · 2025-04-01None$1,088
Sanofi US ServicesConsulting · 2025-01-27None$2,725
GenzymeConsulting · 2025-01-27None$2,725
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $14,012

Payments by company in 2024
Sarepta TherapeuticsNone$5,320
1 payment
  • Consulting · 2024-08-22 · $5,320
Genentech USAEvrysdi$3,450
1 payment
  • Consulting for Evrysdi · 2024-12-13 · $3,450
Merck Sharp & DohmeNone$2,640
1 payment
  • Consulting · 2024-12-18 · $2,640
F. Hoffmann-La Roche AGNone$1,680
1 payment
  • Consulting · 2024-09-30 · $1,680
Roche ProductsEvrysdi$830
1 payment
  • Consulting for Evrysdi · 2024-02-09 · $830
Novartis PharmaceuticalsZolgensma$92
1 payment
  • Meals for Zolgensma · 2024-04-22 · $92

2023: $62,785

Payments by company in 2023
Novartis Gene Therapies Inc. (fka AveXis Inc.)Zolgensma$20,695
20 payments
  • Honoraria for Zolgensma · 2023-10-20 · $4,128
  • Paid to speak or teach for Zolgensma · 2023-10-04 · $75
  • Paid to speak or teach for Zolgensma · 2023-09-27 · $314
  • Paid to speak or teach for Zolgensma · 2023-06-29 · $45
  • Paid to speak or teach for Zolgensma · 2023-06-29 · $914
  • Paid to speak or teach for Zolgensma · 2023-06-29 · $75
  • Paid to speak or teach for Zolgensma · 2023-06-20 · $75
  • Paid to speak or teach for Zolgensma · 2023-06-07 · $1,205
  • Paid to speak or teach for Zolgensma · 2023-05-31 · $2,211
  • Paid to speak or teach for Zolgensma · 2023-05-24 · $75
  • Meals for Zolgensma · 2023-04-26 · $18
  • Paid to speak or teach for Zolgensma · 2023-04-26 · $167
  • Paid to speak or teach for Zolgensma · 2023-04-18 · $42
  • Honoraria for Zolgensma · 2023-04-14 · $4,128
  • Paid to speak or teach for Zolgensma · 2023-03-19 · $640
  • Paid to speak or teach for Zolgensma · 2023-03-19 · $1,067
  • Paid to speak or teach for Zolgensma · 2023-03-07 · $5,333
  • Paid to speak or teach for Zolgensma · 2023-03-02 · $25
  • Paid to speak or teach for Zolgensma · 2023-03-01 · $42
  • Paid to speak or teach for Zolgensma · 2023-02-20 · $118
F. Hoffmann-La Roche AGNone$17,125
5 payments
  • Consulting · 2023-12-01 · $5,040
  • Travel · 2023-12-01 · $737
  • Travel · 2023-12-01 · $10,863
  • Meals · 2023-12-01 · $138
  • Travel · 2023-12-01 · $347
Sarepta TherapeuticsNone$10,622
15 payments
  • Consulting · 2023-10-06 · $4,800
  • Travel · 2023-10-04 · $92
  • Meals · 2023-10-04 · $135
  • Meals · 2023-10-02 · $138
  • Travel · 2023-10-02 · $175
  • Travel · 2023-10-02 · $401
  • Consulting · 2023-10-02 · $4,400
  • Meals · 2023-10-02 · $42
  • Meals · 2023-10-02 · $42
  • Meals · 2023-07-10 · $90
  • Meals · 2023-03-18 · $47
  • Meals · 2023-03-18 · $129
  • Meals · 2023-03-18 · $45
  • Meals · 2023-01-25 · $75
  • Meals · 2023-01-25 · $11
InsmedNone$6,327
6 payments
  • Travel · 2023-05-08 · $160
  • Travel · 2023-05-08 · $160
  • Meals · 2023-05-08 · $143
  • Travel · 2023-05-08 · $299
  • Travel · 2023-05-08 · $3,615
  • Travel · 2023-05-08 · $1,950
Vertex PharmaceuticalsNone$4,275
2 payments
  • Consulting · 2023-08-23 · $1,575
  • Consulting · 2023-08-23 · $2,700
BiogenSpinraza$3,149
3 payments
  • Consulting for Spinraza · 2023-07-10 · $3,065
  • Meals for Spinraza · 2023-06-29 · $66
  • Meals for Spinraza · 2023-03-19 · $17
Roche ProductsEvrysdi$415
1 payment
  • Consulting for Evrysdi · 2023-01-16 · $415
GenentechEvrysdi$176
2 payments
  • Meals for Evrysdi · 2023-12-07 · $141
  • Meals for Evrysdi · 2023-02-27 · $36

2022: $58,328

Payments by company in 2022
Sarepta TherapeuticsNone$25,849
17 payments
  • Consulting · 2022-12-15 · $2,200
  • Consulting · 2022-10-21 · $11,275
  • Meals · 2022-10-09 · $33
  • Meals · 2022-10-09 · $45
  • Meals · 2022-10-09 · $100
  • Travel · 2022-10-09 · $144
  • Travel · 2022-10-09 · $553
  • Travel · 2022-10-09 · $3,698
  • Consulting · 2022-04-14 · $1,960
  • Travel · 2022-04-06 · $673
  • Meals · 2022-04-05 · $10
  • Meals · 2022-04-05 · $15
  • Meals · 2022-04-05 · $32
  • Meals · 2022-04-05 · $125
  • Meals · 2022-04-04 · $62
  • Consulting · 2022-04-04 · $4,815
  • Meals · 2022-01-05 · $110
BiogenSpinraza$20,536
6 payments
  • Meals for Spinraza · 2022-10-13 · $30
  • Consulting for Spinraza · 2022-09-28 · $3,678
  • Consulting for Spinraza · 2022-05-24 · $4,291
  • Consulting · 2022-04-21 · $4,904
  • Consulting for Spinraza · 2022-01-04 · $3,955
  • Consulting for Spinraza · 2022-01-03 · $3,678
Novartis Gene Therapies Inc. (fka AveXis Inc.)Zolgensma$3,975
11 payments
  • Paid to speak or teach for Zolgensma · 2022-12-12 · $42
  • Paid to speak or teach for Zolgensma · 2022-12-09 · $361
  • Paid to speak or teach for Zolgensma · 2022-10-17 · $42
  • Paid to speak or teach for Zolgensma · 2022-10-11 · $375
  • Paid to speak or teach for Zolgensma · 2022-07-25 · $1,778
  • Paid to speak or teach for Zolgensma · 2022-06-15 · $69
  • Paid to speak or teach for Zolgensma · 2022-04-06 · $69
  • Education for Zolgensma · 2022-03-13 · $914
  • Education for Zolgensma · 2022-03-10 · $36
  • Paid to speak or teach · 2022-02-01 · $75
  • Education for Zolgensma · 2022-01-20 · $214
Vertex PharmaceuticalsNone$3,600
1 payment
  • Consulting · 2022-04-13 · $3,600
BioMarin PharmaceuticalNone$2,798
4 payments
  • Paid to speak or teach · 2022-08-26 · $1,800
  • Travel · 2022-08-26 · $495
  • Travel · 2022-08-26 · $367
  • Travel · 2022-08-26 · $136
NS PharmaViltepso$1,326
1 payment
  • Honoraria for Viltepso · 2022-03-31 · $1,326
InsmedNone$114
1 payment
  • Meals · 2022-09-26 · $114
Genentech USAEvrysdi$94
1 payment
  • Meals for Evrysdi · 2022-10-12 · $94
GenentechEvrysdi$36
1 payment
  • Meals for Evrysdi · 2022-11-28 · $36

2021: $20,907

Payments by company in 2021
Novartis Gene Therapies Inc. (fka AveXis Inc.)Zolgensma$14,544
17 payments
  • Education for Zolgensma · 2021-12-07 · $38
  • Education for Zolgensma · 2021-10-06 · $36
  • Education for Zolgensma · 2021-09-23 · $886
  • Meals for Zolgensma · 2021-09-17 · $65
  • Education for Zolgensma · 2021-09-08 · $143
  • Education for Zolgensma · 2021-08-03 · $723
  • Meals for Zolgensma · 2021-07-30 · $87
  • Education for Zolgensma · 2021-06-23 · $2,624
  • Education for Zolgensma · 2021-06-07 · $886
  • Education for Zolgensma · 2021-03-26 · $186
  • Education for Zolgensma · 2021-03-17 · $300
  • Honoraria for Zolgensma · 2021-03-14 · $3,666
  • Education for Zolgensma · 2021-03-12 · $98
  • Honoraria for Zolgensma · 2021-03-10 · $2,811
  • Education for Zolgensma · 2021-03-05 · $546
  • Education for Zolgensma · 2021-03-02 · $1,280
  • Education for Zolgensma · 2021-03-01 · $171
BiogenSpinraza$5,741
2 payments
  • Consulting for Spinraza · 2021-04-16 · $4,803
  • Consulting · 2021-01-04 · $938
Roche ProductsEvrysdi$623
2 payments
  • Consulting for Evrysdi · 2021-12-15 · $208
  • Consulting for Evrysdi · 2021-03-24 · $415

2020: $42,941

Payments by company in 2020
Novartis Gene Therapies Inc. (fka AveXis Inc.)Zolgensma$23,810
43 payments
  • Education for Zolgensma · 2020-12-07 · $4,263
  • Education for Zolgensma · 2020-11-26 · $307
  • Education for Zolgensma · 2020-11-25 · $2,197
  • Education for Zolgensma · 2020-11-19 · $647
  • Education for Zolgensma · 2020-10-29 · $227
  • Education for Zolgensma · 2020-10-19 · $679
  • Education for Zolgensma · 2020-10-13 · $343
  • Education for Zolgensma · 2020-10-13 · $364
  • Education for Zolgensma · 2020-09-07 · $782
  • Education for Zolgensma · 2020-09-07 · $695
  • Education for Zolgensma · 2020-09-02 · $291
  • Education for Zolgensma · 2020-08-20 · $182
  • Education for Zolgensma · 2020-08-10 · $404
  • Honoraria for Zolgensma · 2020-04-30 · $1,125
  • Travel for Zolgensma · 2020-04-20 · $84
  • Honoraria for Zolgensma · 2020-04-20 · $4,000
  • Education for Zolgensma · 2020-03-24 · $496
  • Education for Zolgensma · 2020-03-20 · $227
  • Education for Zolgensma · 2020-03-13 · $227
  • Education for Zolgensma · 2020-03-13 · $191
  • Travel for Zolgensma · 2020-03-06 · $95
  • Education for Zolgensma · 2020-03-06 · $255
  • Education for Zolgensma · 2020-03-06 · $173
  • Education for Zolgensma · 2020-03-06 · $359
  • Travel for Zolgensma · 2020-03-05 · $291
  • Meals for Zolgensma · 2020-03-05 · $100
  • Meals for Zolgensma · 2020-03-05 · $125
  • Travel for Zolgensma · 2020-03-05 · $108
  • Travel for Zolgensma · 2020-02-19 · $1,792
  • Education for Zolgensma · 2020-02-07 · $214
  • Education for Zolgensma · 2020-02-07 · $151
  • Education for Zolgensma · 2020-02-05 · $154
  • Education for Zolgensma · 2020-02-01 · $182
  • Education for Zolgensma · 2020-02-01 · $214
  • Education for Zolgensma · 2020-01-29 · $158
  • Education for Zolgensma · 2020-01-29 · $214
  • Education for Zolgensma · 2020-01-29 · $153
  • Education for Zolgensma · 2020-01-22 · $158
  • Education for Zolgensma · 2020-01-22 · $182
  • Education for Zolgensma · 2020-01-22 · $214
  • Education for Zolgensma · 2020-01-15 · $149
  • Education for Zolgensma · 2020-01-15 · $277
  • Education for Zolgensma · 2020-01-07 · $359
Genentech USANon-Covered Product$9,303
7 payments
  • Paid to speak or teach for Evrysdi · 2020-10-04 · $1,800
  • Meals for Non-Covered Product · 2020-02-10 · $295
  • Consulting for Non-Covered Product · 2020-02-09 · $6,000
  • Travel for Non-Covered Product · 2020-02-09 · $186
  • Meals for Non-Covered Product · 2020-02-09 · $172
  • Travel for Non-Covered Product · 2020-02-09 · $760
  • Travel for Non-Covered Product · 2020-02-09 · $90
BiogenSpinraza$9,077
12 payments
  • Consulting for Spinraza · 2020-10-27 · $900
  • Education · 2020-09-03 · $48
  • Consulting for Spinraza · 2020-07-08 · $750
  • Consulting for Spinraza · 2020-05-01 · $1,350
  • Meals for Spinraza · 2020-02-29 · $26
  • Consulting · 2020-02-06 · $4,000
  • Travel · 2020-02-06 · $65
  • Meals · 2020-02-06 · $98
  • Meals · 2020-01-23 · $189
  • Meals · 2020-01-23 · $79
  • Meals · 2020-01-22 · $163
  • Travel · 2020-01-15 · $1,409
F. Hoffmann-La Roche AGEvrysdi$750
1 payment
  • Education for Evrysdi · 2020-10-12 · $750

2019: $73,609

Payments by company in 2019
AveXisZolgensma$33,412
80 payments
  • Education for Zolgensma · 2019-12-16 · $158
  • Education for Zolgensma · 2019-12-16 · $182
  • Education for Zolgensma · 2019-12-16 · $214
  • Education for Zolgensma · 2019-12-09 · $364
  • Education for Zolgensma · 2019-12-04 · $265
  • Education for Zolgensma · 2019-12-04 · $165
  • Education for Zolgensma · 2019-11-28 · $171
  • Education for Zolgensma · 2019-11-20 · $162
  • Education for Zolgensma · 2019-11-13 · $364
  • Education for Zolgensma · 2019-10-30 · $255
  • Education for Zolgensma · 2019-10-28 · $292
  • Education for Zolgensma · 2019-10-28 · $338
  • Education for Zolgensma · 2019-10-28 · $840
  • Education for Zolgensma · 2019-10-24 · $583
  • Education for Zolgensma · 2019-10-24 · $291
  • Education for Zolgensma · 2019-10-24 · $307
  • Education for Zolgensma · 2019-10-22 · $330
  • Education for Zolgensma · 2019-10-22 · $530
  • Education for Zolgensma · 2019-10-21 · $158
  • Education for Zolgensma · 2019-10-21 · $182
  • Education for Zolgensma · 2019-10-21 · $266
  • Education for Zolgensma · 2019-10-21 · $306
  • Education for Zolgensma · 2019-10-21 · $266
  • Education for Zolgensma · 2019-10-21 · $165
  • Education for Zolgensma · 2019-10-21 · $158
  • Education for Zolgensma · 2019-10-21 · $110
  • Education for Zolgensma · 2019-10-21 · $165
  • Education for Zolgensma · 2019-10-18 · $364
  • Education for Zolgensma · 2019-10-18 · $291
  • Education for Zolgensma · 2019-10-18 · $265
  • Education for Zolgensma · 2019-10-12 · $162
  • Education for Zolgensma · 2019-10-04 · $574
  • Education for Zolgensma · 2019-10-03 · $626
  • Education for Zolgensma · 2019-10-03 · $544
  • Education for Zolgensma · 2019-10-03 · $165
  • Education for Zolgensma · 2019-10-03 · $114
  • Education for Zolgensma · 2019-10-02 · $107
  • Education for Zolgensma · 2019-10-02 · $227
  • Education for Zolgensma · 2019-10-01 · $265
  • Education for Zolgensma · 2019-09-27 · $93
  • Education for Zolgensma · 2019-09-27 · $330
  • Education for Zolgensma · 2019-09-27 · $530
  • Education for Zolgensma · 2019-09-27 · $117
  • Education for Zolgensma · 2019-09-27 · $110
  • Education for Zolgensma · 2019-09-22 · $278
  • Education for Zolgensma · 2019-09-20 · $583
  • Education for Zolgensma · 2019-09-20 · $295
  • Education for Zolgensma · 2019-09-20 · $364
  • Education for Zolgensma · 2019-09-20 · $277
  • Education for Zolgensma · 2019-09-16 · $135
  • Education for Zolgensma · 2019-09-13 · $364
  • Education for Zolgensma · 2019-09-12 · $280
  • Education for Zolgensma · 2019-09-04 · $145
  • Education for Zolgensma · 2019-09-04 · $277
  • Travel · 2019-08-24 · $987
  • Meals · 2019-08-22 · $55
  • Meals · 2019-08-21 · $139
  • Travel · 2019-08-01 · $10,334
  • Education for Zolgensma · 2019-07-19 · $227
  • Education for Zolgensma · 2019-07-05 · $173
  • Education for Zolgensma · 2019-07-05 · $227
  • Education for Zolgensma · 2019-07-02 · $265
  • Education for Zolgensma · 2019-06-30 · $265
  • Education for Zolgensma · 2019-06-30 · $278
  • Education for Zolgensma · 2019-06-30 · $265
  • Education for Zolgensma · 2019-06-29 · $225
  • Education for Zolgensma · 2019-06-29 · $265
  • Education for Zolgensma · 2019-06-28 · $265
  • Education for Zolgensma · 2019-06-28 · $277
  • Education for Zolgensma · 2019-06-27 · $584
  • Education for Zolgensma · 2019-06-27 · $583
  • Meals for Zolgensma · 2019-06-19 · $96
  • Education for Zolgensma · 2019-06-19 · $277
  • Education for Zolgensma · 2019-06-14 · $173
  • Education for Zolgensma · 2019-06-06 · $254
  • Education for Zolgensma · 2019-05-31 · $253
  • Education for Zolgensma · 2019-05-31 · $226
  • Education for Zolgensma · 2019-05-31 · $280
  • Education for Zolgensma · 2019-05-31 · $448
  • Education for Zolgensma · 2019-05-24 · $520
Sarepta TherapeuticsExondys 51$15,894
9 payments
  • Travel for Exondys 51 · 2019-11-20 · $96
  • Consulting for Exondys 51 · 2019-10-31 · $6,800
  • Meals for Exondys 51 · 2019-09-30 · $101
  • Travel for Exondys 51 · 2019-09-30 · $239
  • Meals for Exondys 51 · 2019-09-30 · $44
  • Meals for Exondys 51 · 2019-09-30 · $46
  • Travel for Exondys 51 · 2019-09-30 · $569
  • Travel for Exondys 51 · 2019-09-30 · $7,981
  • Meals for Exondys 51 · 2019-02-19 · $17
F. Hoffmann-La Roche AGNon-Covered Product$14,007
30 payments
  • Paid to speak or teach for Non-Covered Product · 2019-12-31 · $1,245
  • Paid to speak or teach for Non-Covered Product · 2019-12-31 · $908
  • Paid to speak or teach for Non-Covered Product · 2019-12-31 · $1,121
  • Paid to speak or teach for Non-Covered Product · 2019-09-30 · $198
  • Paid to speak or teach for Non-Covered Product · 2019-09-30 · $479
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $141
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $188
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $240
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $201
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $201
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $460
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $601
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $291
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $240
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $106
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $106
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $178
  • Consulting for Non-Covered Product · 2019-04-15 · $3,735
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $528
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $51
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $293
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $46
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $311
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $528
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $286
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $278
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $211
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $286
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $223
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $326
Genentech USANon-Covered Product$6,165
7 payments
  • Meals for Non-Covered Product · 2019-06-01 · $287
  • Travel for Non-Covered Product · 2019-05-31 · $623
  • Consulting for Non-Covered Product · 2019-05-31 · $3,100
  • Travel for Non-Covered Product · 2019-05-31 · $78
  • Travel for Non-Covered Product · 2019-05-31 · $204
  • Paid to speak or teach for Ocrevus · 2019-05-06 · $1,800
  • Meals for Ocrevus · 2019-05-06 · $73
BiogenSpinraza$2,969
12 payments
  • Meals for Spinraza · 2019-06-26 · $64
  • Meals for Spinraza · 2019-06-26 · $84
  • Meals for Spinraza · 2019-06-26 · $60
  • Consulting for Spinraza · 2019-06-25 · $1,200
  • Travel for Spinraza · 2019-06-25 · $351
  • Travel for Spinraza · 2019-06-25 · $117
  • Travel for Spinraza · 2019-06-25 · $205
  • Travel for Spinraza · 2019-06-25 · $368
  • Travel · 2019-05-08 · $37
  • Meals · 2019-05-08 · $70
  • Meals · 2019-05-08 · $112
  • Consulting for Spinraza · 2019-01-02 · $300
Roche ProductsNon-Covered Product$1,038
1 payment
  • Consulting for Non-Covered Product · 2019-07-29 · $1,038
Novartis PharmaceuticalsNone$125
1 payment
  • Meals · 2019-05-07 · $125

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Biogen, Inc. · A Phase 1 Multiple-Ascending-Dose Study To Assess the Safety,Tolerability, and Pharmacokinetics of Biib105 Administered Intrathecally To Adultswith Amyotrophic Lateral Sclerosis With Or Without Poly-Cag Expansion in Theataxin-2 Gene · 2024Their institution$1,418,668
AveXis · Phase I, Open-Label, Dose Comparison Study of Avxs-101 for Sitting But Non-Ambulatory Patients With Spinal Muscular Atrophy · 2019Their institution$831,330
Biogen, Inc. · A Study To Assess the Safety, Tolerability, and Pharmacokinetics of Biib105 in Participants With Amyotrophic Lateral Sclerosis With Or Without Poly-Cytosine-Adenine-Guanine (Cag) Expansion in the Ataxin-2 Gene · 2021Their institution$499,178
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive P · 2019Their institution$476,035
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · Phase I, Open-Label, Dose Comparison Study of Avxs-101 for Sitting But Non-Ambulatory Patients With Spinal Muscular Atrophy · 2020Their institution$431,292
Biogen, Inc. · A Study for Participants With Spinal Muscular Atrophy (Sma) Who Previously Participated in Nusinersen (Isis 396443) Investigational Studies. · 2021Their institution$397,444
Hoffmann-La Roche Limited · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2020Their institution$375,633
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2020Their institution$364,599
Biogen, Inc. · A Study To Assess the Safety, Tolerability, and Pharmacokinetics of Biib078 in Adults With C9orf72-Associated Amyotrophic Lateral Sclerosis · 2020Their institution$349,940
Sarepta Therapeutics, Inc. · 2022Their institution$328,910
Biogen, Inc. · An Open-Label Extension Study for Patients With Spinal Muscular Atrophywho Previously Participated in Investigational Studies of Isis 396443 · 2022Their institution$315,364
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2021Their institution$313,141
Biogen, Inc. · An Extension Study To Assess the Long-Term Safety, Tolerability,Pharmacokinetics, and Effect on Disease Progression of Biib078 Administered Topreviously Treated Adults With C9orf72-Associated Amyotrophic Lateral Sclerosis · 2022Their institution$293,088
Sarepta Therapeutics, Inc. · 2019Their institution$284,649
Biogen, Inc. · A Long-Term Extension Study of Nusinersen (Biib058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in An Investigational Study With Nusinersen. · 2023Their institution$280,981
F. Hoffmann-La Roche AG · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2023Their institution$277,339
Sarepta Therapeutics, Inc. · 2023Their institution$272,496
Biogen, Inc. · A Study for Participants With Spinal Muscular Atrophy (Sma) Who Previously Participated in Nusinersen (Isis 396443) Investigational Studies. · 2019Their institution$261,591
Biogen, Inc. · A Long-Term Extension Study of Nusinersen (Biib058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in An Investigational Study With Nusinersen. · 2024Their institution$256,339
Biogen, Inc. · Escalating Dose and Randomized, Controlled Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy · 2022Their institution$233,325
Biogen, Inc. · Study To Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of Biib078 Administered To Previously Treated Adults C9orf72-Associated Amyotrophic Lateral Sclerosis (Als) · 2021Their institution$232,009
Sarepta Therapeutics, Inc. · 2024Their institution$188,007
Biogen, Inc. · Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy · 2020Their institution$172,940
Hoffmann-La Roche Limited · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2024Their institution$169,657
Biogen, Inc. · A Long-Term Extension Study of Nusinersen (Biib058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in An Investigational Study With Nusinersen. · 2022Their institution$161,427
Biogen, Inc. · A Study To Assess the Safety, Tolerability, and Pharmacokinetics of Biib078 in Adults With C9orf72-Associated Amyotrophic Lateral Sclerosis · 2019Their institution$158,045
Biogen, Inc. · A Study for Participants With Spinal Muscular Atrophy (Sma) Who Previously Participated in Nusinersen (Isis 396443) Investigational Studies. · 2020Their institution$152,424
Biogen, Inc. · Nusinersen in Adults With Spinal Muscular Atrophy: An Open Label Study To Assess Efficacy and Exploratory Endpoints · 2021Their institution$148,875
Hoffmann-La Roche Limited · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2021Their institution$134,148
Biogen, Inc. · Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy · 2021Their institution$127,583
Hoffmann-La Roche Limited · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2019Their institution$117,549
Biogen, Inc. · Exploring Cerebrospinal Fluid Proteomic and Transcriptomic Changes in Sma After Spinraza Treatment · 2023Their institution$116,947
Novartis Pharmaceuticals Corporation · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2024Their institution$116,496
Biogen, Inc. · An Open-Label Extension Study for Patients With Spinal Muscular Atrophywho Previously Participated in Investigational Studies of Isis 396443 · 2024Their institution$115,704
Biogen, Inc. · A Long-Term Extension Study of Nusinersen (Biib058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in An Investigational Study With Nusinersen. · 2025Their institution$114,028
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One Or Two Smn2 Copies Delivering Avxs-101 By Intravenous Infusion · 2020Their institution$107,448
Roche Products Limited · Ascending Dose Study in Boys With DMD · 2020Their institution$107,394
Sarepta Therapeutics, Inc. · Exondys 51 · 2020Their institution$107,206
Biogen, Inc. · Exploring Cerebrospinal Fluid Proteomic and Transcriptomic Changes in Sma After Spinraza Treatment · 2020Their institution$102,329
Roche Products Limited · Study To Assess Efficacy Safety and Tolerability in Ambulatory Boys With DMD · 2019Their institution$100,831
Biogen, Inc. · A Phase 4 Study of Nusinersen (Biib058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec · 2022Their institution$98,224
Biogen, Inc. · Study To Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of Biib078 Administered To Previously Treated Adults C9orf72-Associated Amyotrophic Lateral Sclerosis (Als) · 2020Their institution$96,151
Hoffmann-La Roche Limited · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2022Their institution$93,913
Biogen, Inc. · A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec · 2021Their institution$93,517
Biogen, Inc. · Extension Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy Who Previously Participated in A Study With Nusinersen · 2021Their institution$91,695
Biogen, Inc. · Nusinersen in Adults With Spinal Muscular Atrophy: An Open Label Study To Assess Efficacy and Exploratory Endpoints · 2025Their institution$82,609
Biogen, Inc. · A Study To Assess the Safety, Tolerability, and Pharmacokinetics of Biib078 in Adults With C9orf72-Associated Amyotrophic Lateral Sclerosis · 2021Their institution$80,521
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · Phase I, Open-Label, Dose Comparison Study of Avxs-101 for Sitting But Non-Ambulatory Patients With Spinal Muscular Atrophy · 2021Their institution$77,101
Sarepta Therapeutics, Inc. · Amondys 45 · 2024Their institution$75,680
Biogen, Inc. · An Open-Label Extension Study for Patients With Spinal Muscular Atrophywho Previously Participated in Investigational Studies of Isis 396443 · 2023Their institution$73,848
Biogen, Inc. · Exploring Cerebrospinal Fluid Proteomic and Transcriptomic Changes in Sma After Spinraza Treatment · 2022Their institution$73,092
Sarepta Therapeutics, Inc. · Vyondys 53 · 2020Their institution$70,517
Roche Products Limited · Study To Assess Efficacy Safety and Tolerability in Ambulatory Boys With DMD · 2020Their institution$70,480
Biogen, Inc. · A Phase 4 Study of Nusinersen (Biib058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec · 2023Their institution$66,045
Hoffmann-La Roche Limited · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2019Their institution$65,565
Hoffmann-La Roche Limited · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2023Their institution$65,481
Hoffmann-La Roche Limited · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2024Their institution$65,265
Hoffmann-La Roche Limited · Ascending Dose Study in Boys With DMD · 2019Their institution$63,149
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · Phase I, Open-Label, Dose Comparison Study of Avxs-101 for Sitting But Non-Ambulatory Patients With Spinal Muscular Atrophy · 2022Their institution$60,714
Novartis Pharmaceuticals Corporation · Assessing Pediatric Endpoints in Dm1 (Aspire-Dm1) · 2024Their institution$56,628
Biogen, Inc. · A Phase 3b Study To Evaluate Higher Dose Nusinersen (Biib058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam · 2025Their institution$55,572
Biogen, Inc. · Nusinersen in Adults With Spinal Muscular Atrophy: An Open Label Study To Assess Efficacy and Exploratory Endpoints · 2023Their institution$55,073
Novartis Pharmaceuticals Corporation · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2025Their institution$53,898
Biogen, Inc. · A Phase 1 Multiple-Ascending-Dose Study To Assess the Safety,Tolerability, and Pharmacokinetics of Biib105 Administered Intrathecally To Adultswith Amyotrophic Lateral Sclerosis With Or Without Poly-Cag Expansion in Theataxin-2 Gene · 2023Their institution$51,272
Biogen, Inc. · A Phase 3b Study To Evaluate Higher Dose Nusinersen (Biib058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam · 2024Their institution$50,195
Hoffmann-La Roche Limited · Study To Assess Efficacy Safety and Tolerability in Ambulatory Boys With DMD · 2019Their institution$48,011
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2022Their institution$47,581
Roche Products Limited · Ascending Dose Study in Boys With DMD · 2019Their institution$46,997
Hoffmann-La Roche Limited · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2023Their institution$45,936
F. Hoffmann-La Roche AG · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2023Their institution$45,317
Hoffmann-La Roche Limited · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2019Their institution$38,510
Sarepta Therapeutics, Inc. · Amondys 45 · 2021Their institution$38,064
Hoffmann-La Roche Limited · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2025Their institution$36,695
Biogen, Inc. · Neuropathologic and Autoradiographic Study of Tauopathy in Myotonic Dystrophy (Dm1) · 2021Their institution$33,975
Sarepta Therapeutics, Inc. · 2021Their institution$32,905
Ionis Pharmaceuticals, Inc. · Ion363cs1 · 2025Their institution$32,837
Hoffmann-La Roche Limited · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2022Their institution$32,051
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · A Global Study of A Single, One-Time Dose of Avxs-101 Delivered To Infants With Genetically Diagnosed and Pre-Symptomatic Spinal Muscular Atrophy With Multiple Copies of Smn2 · 2020Their institution$31,484
Biogen, Inc. · A Phase 1 Multiple-Ascending-Dose Study To Assess the Safety,Tolerability, and Pharmacokinetics of Biib105 Administered Intrathecally To Adultswith Amyotrophic Lateral Sclerosis With Or Without Poly-Cag Expansion in Theataxin-2 Gene · 2022Their institution$31,334
PTC Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension · 2020Their institution$31,034
Ionis Pharmaceuticals, Inc. · A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered Ion373 in Patients With Alexander Disease · 2025Their institution$30,726
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2023Their institution$30,287
PTC Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension · 2019Their institution$29,733
Biogen, Inc. · Escalating Dose and Randomized, Controlled Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy · 2023Their institution$28,677
Biogen, Inc. · Nusinersen in Adults With Spinal Muscular Atrophy: An Open Label Study To Assess Efficacy and Exploratory Endpoints · 2024Their institution$27,536
Biogen, Inc. · A Phase 3b Study To Evaluate Higher Dose Nusinersen (Biib058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam · 2023Their institution$27,294
Hoffmann-La Roche Limited · Clinical Trial To Evaluate the Efficacy, Safety, and Tolerability of Ro7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy · 2019Their institution$26,867
F. Hoffmann-La Roche AG · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2023Their institution$25,527
Hoffmann-La Roche Limited · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2020Their institution$24,773
Sarepta Therapeutics, Inc. · 2025Their institution$24,479
Hoffmann-La Roche Limited · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2023Their institution$23,929
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2023Their institution$23,222
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2021Their institution$23,021
Hoffmann-La Roche Limited · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2022Their institution$22,482
Hoffmann-La Roche Limited · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2020Their institution$21,910
PTC Therapeutics, Inc. · An Open-Label, Safety Study for Previously Treated Ataluren Patients With Nonsense Mutation Dystrophinopathy · 2021Their institution$21,342
Sarepta Therapeutics, Inc. · Chart Review · 2019Their institution$21,175
Biogen, Inc. · An Open Label, Single Cohort Study To Assess the Pharmacokinetic Profile of Nusinersen (Biib058) Administered Via the Thecaflex Drx System (Pierre-Pk) · 2025Their institution$20,710
Biogen, Inc. · A Phase 1 Multiple-Ascending-Dose Study To Assess the Safety, Tolerability, and Pharmacokinetics of Biib078 Administered Intrathecally To Adults With C9orf72-Associated Amyotrophic Lateral Sclerosis · 2022Their institution$20,188
Genentech, Inc. · Risdiplam Post Gene Therapy Study Plateau Symptoms Study 2 · 2024Their institution$19,763
Hoffmann-La Roche Limited · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2021Their institution$19,489
Novartis Gene Therapies, Inc. (fka AveXis, Inc.) · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2020Their institution$18,072
PTC Therapeutics, Inc. · An Open-Label, Safety Study for Ataluren (Ptc124) Patients With Nonsense Mutation Dystrophinopathy · 2023Their institution$17,682
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2022Their institution$16,893
Genentech, Inc. · Risdiplam Post Gene Therapy Study Plateau Symptoms Study 2 · 2025Their institution$16,790
VERTEX PHARMACEUTICALS INCORPORATED · A Feasibility Study To Assess the Use of A Digital Device in Subjects With Myotonic Dystrophy Type 1 and Healthy Volunteers · 2023Their institution$16,140
PTC Therapeutics, Inc. · An Open-Label, Safety Study for Ataluren (Ptc124) Patients With Nonsense Mutation Dystrophinopathy · 2025Their institution$14,114
PTC Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension · 2021Their institution$13,913
Hoffmann-La Roche Limited · A Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Sma Participants Sunfish · 2019Their institution$12,078
Hoffmann-La Roche Limited · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2024Their institution$11,332
PTC Therapeutics, Inc. · An Open-Label, Safety Study for Ataluren (Ptc124) Patients With Nonsense Mutation Dystrophinopathy · 2024Their institution$10,643
F. Hoffmann-La Roche AG · A Two Part Seamless, Open-Label, Multicenter Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2020This clinician$9,382
PTC Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension · 2022Their institution$9,360
PTC Therapeutics, Inc. · An Open-Label, Safety Study for Ataluren (Ptc124) Patients With Nonsense Mutation Dystrophinopathy · 2022Their institution$8,172
Biogen, Inc. · Escalating Dose and Randomized, Controlled Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy · 2025Their institution$7,805
Biogen, Inc. · A Phase 4 Study of Nusinersen (Biib058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec · 2024Their institution$7,486
Biogen, Inc. · A Phase 4 Study of Nusinersen (Biib058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec · 2025Their institution$6,195
Biogen, Inc. · Escalating Dose and Randomized, Controlled Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy · 2024Their institution$5,035
PTC Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension · 2025Their institution$5,000
F. Hoffmann-La Roche AG · A Two-Part Seamless, Multi-Center Randomized, Placebo-Controlled, Doubleblind Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients. · 2020This clinician$4,834
PTC Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension · 2023Their institution$4,159
SANOFI US SERVICES INC. · Pompe Disease Registry · 2023Their institution$3,475
Sarepta Therapeutics, Inc. · Amondys 45 · 2022Their institution$3,186
Biogen, Inc. · An Extension Study To Assess the Long-Term Safety, Tolerability,Pharmacokinetics, and Effect on Disease Progression of Biib078 Administered Topreviously Treated Adults With C9orf72-Associated Amyotrophic Lateral Sclerosis · 2023Their institution$3,129
F. Hoffmann-La Roche AG · Study of Rg7916 in Pre Symptomatic Sma Patients · 2023This clinician$2,749
Sarepta Therapeutics, Inc. · Amondys 45 · 2023Their institution$2,560
Hoffmann-La Roche Limited · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2021Their institution$2,281
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2021This clinician$2,000
Biogen, Inc. · Nusinersen in Adults With Spinal Muscular Atrophy: An Open Label Study To Assess Efficacy and Exploratory Endpoints · 2022Their institution$1,972
F. Hoffmann-La Roche AG · An Open-Label Study To Investigate the Safety, Tolerability, and Pharmacokineticspharmacodynamics of Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2020This clinician$1,802
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2022This clinician$1,750
F. Hoffmann-La Roche AG · Baseline Demographics and Clinical Characteristics of Risdiplam-Treated Individuals With Sma From the Pediatric Neuromuscular Clinical Research (Pncr) Registry · 2025This clinician$1,681
F. Hoffmann-La Roche AG · An Open-Label Study To Investigate the Safety, Tolerability, and Pharmacokineticspharmacodynamics of Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy, A Two-Part Seamless, Multi-Center Randomized, Placebo-Controlled, Doubleblind Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients., A Two Part Seamless, Open-Label, Multicenter Study To Investigate the Safety, in · 2020This clinician$1,539
GENZYME CORPORATION · A Phase 4, Open Label, Prospective Study in Patients With Pompe Disease To Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000l Scale · 2019This clinician$1,352
F. Hoffmann-La Roche AG · An Open-Label Study To Investigate the Safety, Tolerability, and Pharmacokineticspharmacodynamics of Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy, A Two-Part Seamless, Multi-Center Randomized, Placebo-Controlled, Doubleblind Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients., A Two Part Seamless, Open-Label, Multicenter Study To Investigate the Safety, Tolerabilit · 2021This clinician$1,292
F. Hoffmann-La Roche AG · A Two-Part Seamless, Multi-Center Randomized, Placebo-Controlled, Doubleblind Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients. · 2021This clinician$1,019
F. Hoffmann-La Roche AG · A Two Part Seamless, Open-Label, Multicenter Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2021This clinician$1,009
F. Hoffmann-La Roche AG · Ro7034067 in Infants With Type 1 Spinal Muscular Atrophy · 2024This clinician$989
Novartis Gene Therapies, Inc. (fka Avexis, Inc.) · Research Medical Writing and Publication Support · 2024This clinician$963
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2023This clinician$750
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment Naive Patients With Late Onset Pompe Disease · 2021This clinician$750
Novartis Pharmaceuticals Corporation · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2022Their institution$737
F. Hoffmann-La Roche AG · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2025This clinician$708
GENZYME CORPORATION · A Phase 4, Open Label, Prospective Study in Patients With Pompe Disease To Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000l Scale · 2020This clinician$524
F. Hoffmann-La Roche AG · Safety Update: Risdiplam Clinical Trial Program for Spinal Muscular Atrophy (Sma) · 2025This clinician$504
F. Hoffmann-La Roche AG · Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2025This clinician$501
F. Hoffmann-La Roche AG · Firefish Parts 1 and 2: 5-Year Efficacy and Safety of Risdiplam in Type 1 Sma · 2025This clinician$459
F. Hoffmann-La Roche AG · Systemic Gene Delivery Clinical Trial for Duchenne Muscular Dystrophy (DMD) · 2023This clinician$385
F. Hoffmann-La Roche AG · Safety Update: Risdiplam Clinical Trial Program for Sma · 2023This clinician$354
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Nave · 2020This clinician$340
Biogen, Inc. · A Phase 3b Study To Evaluate Higher Dose Nusinersen (Biib058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam · 2022Their institution$320
F. Hoffmann-La Roche AG · A Gene Delivery Study To Evaluate the Safety of and Expression From Srp-9001 in Duchenne Muscular Dystrophy (DMD) (Endeavor) · 2024This clinician$307
F. Hoffmann-La Roche AG · Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients · 2020This clinician$303
Novartis Pharmaceuticals Corporation · Restore Registry · 2025This clinician$249
F. Hoffmann-La Roche AG · Study of Rg7916 in Pre Symptomatic Sma Patients, An Open-Label Study To Investigate the Safety, Tolerability, and Pharmacokineticspharmacodynamics of Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy, A Two-Part Seamless, Multi-Center Randomized, Placebo-Controlled, Doubleblind Study To Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Ro7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients., A Two Part Seamless, Open-Label, Multice · 2021This clinician$220
GENZYME CORPORATION · A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Neogaa (Gz402666) and Alglucosidase Alfa in Treatment-Naive Patients With Late-Onset Pompe Disease · 2020This clinician$217
Biogen, Inc. · Study of Nusinersen (Biib058) in Participants With Spinal Muscular Atrophy · 2020This clinician$136
F. Hoffmann-La Roche AG · An Open-Label Study To Investigate the Safety, Tolerability, and Pharmacokineticspharmacodynamics of Ro7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy · 2021This clinician$71
Novartis Pharmaceuticals Corporation · A Long-Term Follow-Up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving Avxs-101 · 2023Their institution$70

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1447291992
Licence
CA G52734California G52734: Current · expires 2027-04-30
Trained
University of Minnesota Medical School, 1977
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 2084N0008X (2084N0008X); Neurology (2084N0400X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-06-08
NPI last updated
2023-11-09
NPI record certified
2023-11-09

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 725 Welch Rd, Palo Alto, CA, 94304